Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

The agency launched the Commissioner's National Priority Voucher pilot program to quickly approve products that could address national interests.

Trial initiation triggered a $250 million payment to SystImmune from Bristol Myers Squibb, under a 2023 collaboration and license agreement.

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzen, China-based firm. Pregene is entitled to receive ...

Patients with a very rare immune disorder who have gotten the gene therapy have experienced sustained long-term immune ...

NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.

Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.

The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.

The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.